Podium to Practice: Chicago 2026 – GU: RMC
OR
Studies / Trials Discussed
4520 – Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC): A collaborative multi-institutional study.
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
Studies/trials discussed:
4520 – Prospective clinical activity and preclinical basis of panitumumab-based EGFR blockade in SMARCB1-deficient renal medullary carcinoma (RMC): A collaborative multi-institutional study.
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.